July 15, 2009

New Hodgkin’s lymphoma treatment reported

U.S. medical scientists say they have developed a new chemotherapy regimen for pediatric Hodgkin's lymphoma patients.

Dr. Cindy Schwartz of Brown University Medical School's Hasbro Children's Hospital said the new treatment enhances efficacy through dose-dense drug delivery, while simultaneously reducing the long-term risks presented by high cumulative dose chemotherapy.

Schwartz said current therapy for the disease in the United States did not include the most modern treatment models, in large part because it was one of the first malignancies for which a curative chemotherapy regimen was developed.

For decades, the chemotherapy regimens known as MOPP and ABVD had been the standard treatment options for these patients, said Schwartz. However, while they yielded excellent survival rates, they often resulted in long-term effects from toxicity, including infertility, second malignancy and cardiopulmonary toxicity. With the new treatment paradigm we've developed "¦ we've been able to cure the cancer while reducing the risk of long-term effects on our patients.

Schwartz and her colleagues report their findings in the online early edition of the journal Blood.